Pub Date : 2026-01-01DOI: 10.1016/j.jscai.2025.104106
Jeffrey C.Y. Lee MBBS , Timothy H.H. Kam MD , Yasunari Sakamoto MD , Guangming Tan MBChB , Bryan P. Yan MBBS, MD
Eccentric calcified plaque remains a challenge in the endovascular treatment of peripheral arterial disease despite technological advancements. The "aggressive wire recanalization in calcified atheroma and dilatation" technique was invented to overcome this by intentional intraplaque wiring followed by atherectomy; however, distal embolization can ensue. Substitution with intravascular lithotripsy may be safer and equally effective. To the best of our knowledge, we performed the first case of intentional intraplaque lithotripsy to successfully treat a claudicant patient with heavily calcified bilateral superficial femoral arteries without complications. This may be considered a new technique variation to treat eccentric calcium.
{"title":"First Report of Intentional Intraplaque Lithotripsy After Aggressive Wire Recanalization in Calcified Atheroma and Dilatation (ARCADIA-SHOCK)","authors":"Jeffrey C.Y. Lee MBBS , Timothy H.H. Kam MD , Yasunari Sakamoto MD , Guangming Tan MBChB , Bryan P. Yan MBBS, MD","doi":"10.1016/j.jscai.2025.104106","DOIUrl":"10.1016/j.jscai.2025.104106","url":null,"abstract":"<div><div>Eccentric calcified plaque remains a challenge in the endovascular treatment of peripheral arterial disease despite technological advancements. The \"aggressive wire recanalization in calcified atheroma and dilatation\" technique was invented to overcome this by intentional intraplaque wiring followed by atherectomy; however, distal embolization can ensue. Substitution with intravascular lithotripsy may be safer and equally effective. To the best of our knowledge, we performed the first case of intentional intraplaque lithotripsy to successfully treat a claudicant patient with heavily calcified bilateral superficial femoral arteries without complications. This may be considered a new technique variation to treat eccentric calcium.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"5 1","pages":"Article 104106"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jscai.2025.104107
Jen-Kuang Lee MD , Richard Pin MD , Shirley Jansen MBChB, PhD , Anderson P. Mehrle MD , Yazan Khatib MD , Prakash Krishnan MD , Brian G. DeRubertis MD , Ramon L. Varcoe MBBS, MS, PhD, MMed , Anette Popiel MS , Sandeep C. Pingle MD, PhD , Karine Ruster PhD , Sahil A. Parikh MD
Background
The most severe manifestation of peripheral artery disease, chronic limb-threatening ischemia, is associated with limited treatment options for below-the-knee (BTK) arteries. The Esprit BTK everolimus-eluting resorbable scaffold system (Abbott), now approved by the U.S. Food and Drug Administration for the treatment of infrapopliteal lesions in patients with chronic limb-threatening ischemia, was evaluated in the LIFE-BTK randomized controlled trial. LIFE-BTK included a nonrandomized substudy evaluating the pharmacokinetic (PK) profile of everolimus eluted from the scaffold.
Methods
The PK substudy enrolled 9 subjects across 2 treatment groups (with or without drug-coated balloon use for inflow lesion and/or nontarget lesion treatment). Blood concentration-time profiles and PK parameters were determined at multiple time points and compared with prior PK results from the Absorb bioresorbable vascular scaffold.
Results
The number of implanted scaffolds averaged 6.6 ± 0.9, with a total length ranging from 180 to 256 mm and an everolimus dose ranging from 1397 to 2074 μg per subject. The last time point at which everolimus could be quantified ranged from 168 to 720 hours, and in most cases, the blood concentrations dropped below the lower limit of quantification (0.1 ng/mL) before 720 hours. Peak blood everolimus levels were followed by a biexponential decline, with terminal phase half-life ranging from 65.6 to 211.2 hours. A regression analysis using dose-normalized maximum blood everolimus concentration and area under the blood concentration-time curve confirmed similar everolimus exposure across the treatment groups.
Conclusions
The present substudy assessed the PK of everolimus delivered by Esprit BTK in the planned treatment of narrowed infrapopliteal lesions. This study confirms that the PK profile of everolimus eluted from the Esprit BTK scaffold results in limited systemic exposure and is considered to be safe and well tolerated.
{"title":"Pharmacokinetic Profile of Everolimus Eluted From the Esprit BTK Scaffold: A LIFE-BTK Pharmacokinetics Substudy","authors":"Jen-Kuang Lee MD , Richard Pin MD , Shirley Jansen MBChB, PhD , Anderson P. Mehrle MD , Yazan Khatib MD , Prakash Krishnan MD , Brian G. DeRubertis MD , Ramon L. Varcoe MBBS, MS, PhD, MMed , Anette Popiel MS , Sandeep C. Pingle MD, PhD , Karine Ruster PhD , Sahil A. Parikh MD","doi":"10.1016/j.jscai.2025.104107","DOIUrl":"10.1016/j.jscai.2025.104107","url":null,"abstract":"<div><h3>Background</h3><div>The most severe manifestation of peripheral artery disease, chronic limb-threatening ischemia, is associated with limited treatment options for below-the-knee (BTK) arteries. The Esprit BTK everolimus-eluting resorbable scaffold system (Abbott), now approved by the U.S. Food and Drug Administration for the treatment of infrapopliteal lesions in patients with chronic limb-threatening ischemia, was evaluated in the LIFE-BTK randomized controlled trial. LIFE-BTK included a nonrandomized substudy evaluating the pharmacokinetic (PK) profile of everolimus eluted from the scaffold.</div></div><div><h3>Methods</h3><div>The PK substudy enrolled 9 subjects across 2 treatment groups (with or without drug-coated balloon use for inflow lesion and/or nontarget lesion treatment). Blood concentration-time profiles and PK parameters were determined at multiple time points and compared with prior PK results from the Absorb bioresorbable vascular scaffold.</div></div><div><h3>Results</h3><div>The number of implanted scaffolds averaged 6.6 ± 0.9, with a total length ranging from 180 to 256 mm and an everolimus dose ranging from 1397 to 2074 μg per subject. The last time point at which everolimus could be quantified ranged from 168 to 720 hours, and in most cases, the blood concentrations dropped below the lower limit of quantification (0.1 ng/mL) before 720 hours. Peak blood everolimus levels were followed by a biexponential decline, with terminal phase half-life ranging from 65.6 to 211.2 hours. A regression analysis using dose-normalized maximum blood everolimus concentration and area under the blood concentration-time curve confirmed similar everolimus exposure across the treatment groups.</div></div><div><h3>Conclusions</h3><div>The present substudy assessed the PK of everolimus delivered by Esprit BTK in the planned treatment of narrowed infrapopliteal lesions. This study confirms that the PK profile of everolimus eluted from the Esprit BTK scaffold results in limited systemic exposure and is considered to be safe and well tolerated.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"5 1","pages":"Article 104107"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jscai.2025.104065
Michael Vlach MD , Aqsa Choudhry MSc , Rhythm Vasudeva MD , Mohinder Vindhyal MD , Prasad Gunasekaran MD , Gaurav Parmar MD , Georges Haj MD , J.D. Serfas MD , Mark Wiley MD , Peter Tadros MD , Eric Hockstad MD , Anthony Spaedy MD , Seth Decamp MD , Kamal Gupta MD
Background
Radial artery pseudoaneurysm (RAP) is a rare complication of procedural radial access. There is a paucity of data regarding clinical presentation, characteristics, and management.
Methods
We identified patients with RAP by querying our center’s electronic medical records. A manual chart review was performed, and a descriptive analysis was conducted.
Results
We identified 35 patients with RAP (mean age, 68.3 years; 62.9% women). Of these, 71.4 % of pseudoaneurysms were caused by arterial access for coronary procedures. Sixty percent were on anticoagulation. The most common symptoms were swelling (88.6%) and pain (45.7%). The median time from procedure to diagnosis was 13 days (IQR, 1-33.5 days), and the median time from procedure to symptom onset was 1 day (IQR, 0-8.5 days). Initial treatment modality was mechanical compression in 19 patients (54.3%). Of those who underwent compression, the RAP thrombosed in 9 patients (47.4%) and failed in 10 patients (52.6%) who then underwent successful surgical repair. Those with RAP resolution with compression had a shorter time to ultrasound diagnosis (1 vs 6.5 days) and smaller size (1.6 vs 2.4 cm). Surgery was successful in all but 1 patient.
Conclusion
Study findings show that RAPs often present several days after the index procedure, although symptoms occur much earlier. The RAPs occur disproportionately in women and those on anticoagulation. Compression is successful in only half the patients. Earlier presentation and smaller size predict success. Surgery is almost universally successful, and thrombin injection is rarely used. Our results suggest a need for prospective studies to assess strategies for earlier identification of RAP.
{"title":"Clinical Presentation, Management, and Outcomes of Access-Related Radial Artery Pseudoaneurysms: A Single-Center, Retrospective Cohort Study","authors":"Michael Vlach MD , Aqsa Choudhry MSc , Rhythm Vasudeva MD , Mohinder Vindhyal MD , Prasad Gunasekaran MD , Gaurav Parmar MD , Georges Haj MD , J.D. Serfas MD , Mark Wiley MD , Peter Tadros MD , Eric Hockstad MD , Anthony Spaedy MD , Seth Decamp MD , Kamal Gupta MD","doi":"10.1016/j.jscai.2025.104065","DOIUrl":"10.1016/j.jscai.2025.104065","url":null,"abstract":"<div><h3>Background</h3><div>Radial artery pseudoaneurysm (RAP) is a rare complication of procedural radial access. There is a paucity of data regarding clinical presentation, characteristics, and management.</div></div><div><h3>Methods</h3><div>We identified patients with RAP by querying our center’s electronic medical records. A manual chart review was performed, and a descriptive analysis was conducted.</div></div><div><h3>Results</h3><div>We identified 35 patients with RAP (mean age, 68.3 years; 62.9% women). Of these, 71.4 % of pseudoaneurysms were caused by arterial access for coronary procedures. Sixty percent were on anticoagulation. The most common symptoms were swelling (88.6%) and pain (45.7%). The median time from procedure to diagnosis was 13 days (IQR, 1-33.5 days), and the median time from procedure to symptom onset was 1 day (IQR, 0-8.5 days). Initial treatment modality was mechanical compression in 19 patients (54.3%). Of those who underwent compression, the RAP thrombosed in 9 patients (47.4%) and failed in 10 patients (52.6%) who then underwent successful surgical repair. Those with RAP resolution with compression had a shorter time to ultrasound diagnosis (1 vs 6.5 days) and smaller size (1.6 vs 2.4 cm). Surgery was successful in all but 1 patient.</div></div><div><h3>Conclusion</h3><div>Study findings show that RAPs often present several days after the index procedure, although symptoms occur much earlier. The RAPs occur disproportionately in women and those on anticoagulation. Compression is successful in only half the patients. Earlier presentation and smaller size predict success. Surgery is almost universally successful, and thrombin injection is rarely used. Our results suggest a need for prospective studies to assess strategies for earlier identification of RAP.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"5 1","pages":"Article 104065"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jscai.2025.104042
Asim Mohiuddin MD, Mohammed Salih MD, Abdallah Assaf MD, Adam Abd El-Kader MS, Will Hobbs MS, Ahmed Elkaialy MD, Ralph Matar MD, Karim Al-Azizi MD
Left atrial appendage occlusion has become an important minimally invasive treatment option for patients with atrial fibrillation who previously interrupted or permanently discontinued oral anticoagulation due to bleeding risks or complications. The effectiveness of the therapy relies on the safety of device deployment and the complete closure of the left atrial appendage (LAA) with no peridevice leaks. The variability of the LAA anatomy seen on preprocedural imaging requires a tailored approach for successful exclusion. We hereby present a patient with a large multilobar LAA that required 2 simultaneous Amulet devices to achieve complete exclusion of the appendage.
{"title":"Simultaneous Dual Left Atrial Appendage Occlusion Devices in a Single Setting—A Case Report","authors":"Asim Mohiuddin MD, Mohammed Salih MD, Abdallah Assaf MD, Adam Abd El-Kader MS, Will Hobbs MS, Ahmed Elkaialy MD, Ralph Matar MD, Karim Al-Azizi MD","doi":"10.1016/j.jscai.2025.104042","DOIUrl":"10.1016/j.jscai.2025.104042","url":null,"abstract":"<div><div>Left atrial appendage occlusion has become an important minimally invasive treatment option for patients with atrial fibrillation who previously interrupted or permanently discontinued oral anticoagulation due to bleeding risks or complications. The effectiveness of the therapy relies on the safety of device deployment and the complete closure of the left atrial appendage (LAA) with no peridevice leaks. The variability of the LAA anatomy seen on preprocedural imaging requires a tailored approach for successful exclusion. We hereby present a patient with a large multilobar LAA that required 2 simultaneous Amulet devices to achieve complete exclusion of the appendage.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"5 1","pages":"Article 104042"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A New Lens on Radiation Risk: Why Outliers Matter","authors":"Zaid Almarzooq MD, MPH , Celina M. Yong MD, MBA, MSc","doi":"10.1016/j.jscai.2025.104118","DOIUrl":"10.1016/j.jscai.2025.104118","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"5 1","pages":"Article 104118"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jscai.2025.104113
Khansa Ahmad MD , Islam Y. Elgendy MD
{"title":"Sex-Specific Coronary Artery Calcium Score Thresholds Predictive of Obstructive Coronary Artery Disease: Ready for Prime Time?","authors":"Khansa Ahmad MD , Islam Y. Elgendy MD","doi":"10.1016/j.jscai.2025.104113","DOIUrl":"10.1016/j.jscai.2025.104113","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"5 1","pages":"Article 104113"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jscai.2025.104051
Rhian E. Davies DO, MS, David A. Cox MD, Lancer Smith MS
{"title":"Standards for Comparative Radiation Protection Research","authors":"Rhian E. Davies DO, MS, David A. Cox MD, Lancer Smith MS","doi":"10.1016/j.jscai.2025.104051","DOIUrl":"10.1016/j.jscai.2025.104051","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"5 1","pages":"Article 104051"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jscai.2025.104056
Andres Cordova Sanchez MD , Jesse Kane MD , Tanush Gupta MD , Hanna R. Murphy PhD , Alyssa H. Harris MPH , Harold L. Dauerman MD
Background
Current guidelines recommend implantation of a microaxial flow pump (mAFP) for selected patients with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (STEMI-CS). Although the DanGer Shock trial showed a mortality benefit with mAFP, a secondary analysis suggested that older adult patients may not experience the same benefit. This study evaluated the temporal trends in mAFP utilization and hospital mortality in older (≥75 years) vs younger STEMI-CS patients.
Methods
Using the International Classification of Diseases, 10th Revision (ICD-10-CM) procedure codes from 344 hospitals with continuous data between 2016 and 2024 from the Vizient Clinical Data Base, we identified 20,692 patients undergoing percutaneous coronary intervention (PCI) for STEMI-CS. Temporal trends in mAFP use and mortality were stratified by older (≥75 years) vs younger age groups. Multivariable logistic regressions identified the predictors of hospital mortality.
Results
Among 20,692 STEMI-CS patients undergoing PCI, 25% were ≥75 years. Older age was the strongest independent predictor of hospital mortality for STEMI-CS patients (odds ratio, 1.87; 95% CI, 1.75-2.00). Between 2016 and 2024, mAFP use for STEMI-CS increased from 9.3% to 21.5% in patients ≥75 years old and from 14% to 25.6% in patients <75 years old (P value for trend = .05 and .02, respectively). Mortality declined in mAFP patients <75 years old (45% in 2016 vs 38% in 2024; P = .003). The mortality rate for older PCI patients with STEMI-CS and mAFP utilization was consistently above 50%.
Conclusions
Approximately 1 in 5 older STEMI-CS patients received mAFP, with use more than doubling since 2016. Although mortality declined significantly in mAFP-treated younger STEMI-CS PCI patients, mortality in the older group remained approximately 60% higher than that of younger patients at all time points.
{"title":"National Trends in Impella Utilization for Older Adult Patients With ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock","authors":"Andres Cordova Sanchez MD , Jesse Kane MD , Tanush Gupta MD , Hanna R. Murphy PhD , Alyssa H. Harris MPH , Harold L. Dauerman MD","doi":"10.1016/j.jscai.2025.104056","DOIUrl":"10.1016/j.jscai.2025.104056","url":null,"abstract":"<div><h3>Background</h3><div>Current guidelines recommend implantation of a microaxial flow pump (mAFP) for selected patients with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (STEMI-CS). Although the DanGer Shock trial showed a mortality benefit with mAFP, a secondary analysis suggested that older adult patients may not experience the same benefit. This study evaluated the temporal trends in mAFP utilization and hospital mortality in older (≥75 years) vs younger STEMI-CS patients.</div></div><div><h3>Methods</h3><div>Using the International Classification of Diseases, 10th Revision (ICD-10-CM) procedure codes from 344 hospitals with continuous data between 2016 and 2024 from the Vizient Clinical Data Base, we identified 20,692 patients undergoing percutaneous coronary intervention (PCI) for STEMI-CS. Temporal trends in mAFP use and mortality were stratified by older (≥75 years) vs younger age groups. Multivariable logistic regressions identified the predictors of hospital mortality.</div></div><div><h3>Results</h3><div>Among 20,692 STEMI-CS patients undergoing PCI, 25% were ≥75 years. Older age was the strongest independent predictor of hospital mortality for STEMI-CS patients (odds ratio, 1.87; 95% CI, 1.75-2.00). Between 2016 and 2024, mAFP use for STEMI-CS increased from 9.3% to 21.5% in patients ≥75 years old and from 14% to 25.6% in patients <75 years old (<em>P</em> value for trend = .05 and .02, respectively). Mortality declined in mAFP patients <75 years old (45% in 2016 vs 38% in 2024; <em>P</em> = .003). The mortality rate for older PCI patients with STEMI-CS and mAFP utilization was consistently above 50%.</div></div><div><h3>Conclusions</h3><div>Approximately 1 in 5 older STEMI-CS patients received mAFP, with use more than doubling since 2016. Although mortality declined significantly in mAFP-treated younger STEMI-CS PCI patients, mortality in the older group remained approximately 60% higher than that of younger patients at all time points.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"5 1","pages":"Article 104056"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jscai.2025.104197
{"title":"Cover","authors":"","doi":"10.1016/j.jscai.2025.104197","DOIUrl":"10.1016/j.jscai.2025.104197","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"5 1","pages":"Article 104197"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145996399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号